Ocular Toxicity from Antibody-Drug Conjugates in Cancer Therapy: A Review

A review document compiling data on ocular toxicity reported during clinical development and postmarketing surveillance of all currently approved antibody-drug conjugates (ADCs). The document analyzes potential mechanisms, summarizes reported ocular adverse events and their incidence, and explores mitigation strategies. It was authored by Junxiang Zhou and last updated on 2026-04-27.

Use Cases

• Summarizing incidence rates of ocular adverse events across approved ADCs based on the compiled clinical and postmarketing data.
• Analyzing potential mechanisms underlying ADC-associated ocular toxicity as discussed in the review.
• Informing toxicity management strategies for early detection and monitoring of ocular side effects in ADC therapy.
• Exploring drug development strategies for mitigating ocular toxicity through target selection and payload optimization.

Strengths

• Focuses on a specific and under-prioritized adverse event (ocular toxicity) in a major therapeutic class.
• Compiles data from both clinical development and postmarketing surveillance phases for all approved ADCs.
• File is licensed under CC-BY-4.0, allowing for reuse with attribution.

Limitations

• The dataset is a 17.6 KB DOCX file, indicating a very limited scope and likely a text document rather than structured data.
• Row count and column-level documentation are absent; the content's structure must be inspected after download.
• Last updated 2026-04-27 05:16:33; freshness should be verified as the date is in the future.

Provenance

Source

figshare

Collection Method

Compilation and review of reported data from clinical trials and postmarketing surveillance.

Freshness

Last updated 2026-04-27 05:16:33